Zydus Cadila has received the final approval from the U.S. Food and Drug Administration (USFDA) to market Felbamate Tablets USP in strengths of 400 mg and 600 mg. Felbamate is an oral drug used to treat seizures in people with epilepsy. It will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
